Cargando…
BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency
Persistent latent reservoir in resting CD4+ T cells is a major obstacle in curing HIV-1 infection. Effective strategies for eradication of the HIV-1 reservoir are urgently needed. We report here for the first time that two BET inhibitors, RVX-208, which has entered phase II clinical trials for diver...
Autores principales: | Lu, Panpan, Shen, Yinzhong, Yang, He, Wang, Yanan, Jiang, Zhengtao, Yang, Xinyi, Zhong, Yangcheng, Pan, Hanyu, Xu, Jianqing, Lu, Hongzhou, Zhu, Huanzhang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709369/ https://www.ncbi.nlm.nih.gov/pubmed/29192216 http://dx.doi.org/10.1038/s41598-017-16816-1 |
Ejemplares similares
-
RVX 208
Publicado: (2012) -
The bromodomain and extraterminal domain inhibitor bromosporine synergistically reactivates latent HIV-1 in latently infected cells
por: Pan, Hanyu, et al.
Publicado: (2017) -
PEBP1 suppresses HIV transcription and induces latency by inactivating MAPK/NF‐κB signaling
por: Yang, Xinyi, et al.
Publicado: (2020) -
The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb
por: Lu, Panpan, et al.
Publicado: (2016) -
RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
por: McLure, Kevin G., et al.
Publicado: (2013)